Table 4 PDX model in targeted therapy research

From: Patient-derived xenograft models in cancer therapy: technologies and applications

Reference	Drug name	Drug administration method	Gene target	Cancer type	Application scenario
Schueler et al.²⁶⁶	Gefitinib	Oral gavage	EGFR	NSCLC	Drug resistance mechanism study
Zhang et al.²⁶⁷	ASK120067	Oral gavage	EGFR	NSCLC	Novel drug validation
Chew et al.²⁶⁸	AZD4547, BLU9931	oral gavage	FGFR1, FGFR2, FGFR4	breast cancer	Therapeutic target identification
Krytska et al.²⁶⁹	crizotinib	Intraperitoneal Injections	ALK	Neuroblastoma	Drug combination validation
Shattuck-Brandt et al.²⁷⁰	KRT-232	oral gavage	MDM2	Metastatic Melanoma	Therapeutic target identification
Kinsey et al.²⁷¹	trametinib	oral gavage	MEK	Pancreatic ductal adenocarcinoma	Drug combination validation
Coussy et al.²⁷²	BYL-719;	oral gavage	PI3K	PIK3CA-mutated metaplastic breast cancer	Drug combination validation
Coussy et al.²⁷²	selumetinib	oral gavage	MEK	PIK3CA-mutated metaplastic breast cancer	Drug combination validation
Coussy et al.¹⁸¹	BAY80-6946;	N/A	PI3K p110α subunit	enzalutamide-resistant luminal androgen receptor triple-negative breast cancer	Therapeutic target identification
	PF-04691502;		mTOR and PI3K
	AZD2014		mTORC1 and mTORC2
Hsu et al.²⁷³	MLN0128	oral gavage	dual mTOR complex HER 2	HR + /HER2 + Breast Cancer	Drug combination validation
Hsu et al.²⁷³	trastuzumab	intraperitoneal injection	dual mTOR complex HER 2	HR + /HER2 + Breast Cancer	Drug combination validation
Harris et al.²⁷⁴	pertuzumab/trastuzumab	oral gavage	HER2	Ovarian cancer	Drug combination validation
Hashimoto et al.²⁷⁵	U3-1402	intravenous	HER3	HER3 positive cancer	Novel drug validation
Reddy et al.²⁷⁶	Pan-HER	Intraperitoneal injection	Pan-HER antibody mixture against EGFR, HER2, and HER3	TNBC	Drug combination validation
Odintsov et al.²⁷⁷	GSK2849330	intraperitoneal injection	HER3	NRG1-rearranged lung adenocarcinoma	Drug combination validation
Chen et al.²⁷⁸	compound 36 l	Intraperitoneal injection	KRAS‒PDEδ	pancreatic tumor	Novel drug preclinical validation
Barrette et al.²⁷⁹	Verteporfin	Intraperitoneal injection	YAP-TEAD	Glioblastoma	Novel drug preclinical validation
Hemming et al.²⁸⁰	YKL-5–124	Intraperitoneal injection	CDK7	Leiomyosarcoma	Therapeutic target identification
Gebreyohannes et al.¹⁹³	Avapritinib	Oral gavage	Mutated KIT	Gastrointestinal Stromal Tumors	Novel drug preclinical validation
Karalis et al.²⁸¹	Lenvatinib	Oral gavage	Multitargeted tyrosine kinase inhibitor	Gastric cancer	Novel drug preclinical validation
Dankner et al.²⁸²	Dabrafenib, encorafenib	Oral gavage	BRAF	Class II BRAF mutant melanoma	Drug combination validation
Dankner et al.²⁸²	Trametinib and binimetinib	Oral gavage	MEK	Class II BRAF mutant melanoma	Drug combination validation
Knudsen et al.²⁸³	Palbociclib	Oral gavage	CDK4/6	Pancreatic cancer	Drug combination validation
Knudsen et al.²⁸³	Trametinib	Oral gavage	MEK	Pancreatic cancer	Drug combination validation
Zhao et al.¹⁸⁹	Neratinib	Oral gavage	Neratinib with CDK4/6, mTOR, and MEK inhibitors for the treatment of HER2 + cancer.	Pan-cancer	Drug combination validation
Yao et al.⁴⁸	Cetuximab	Intraperitoneal injection	EGFR	Colorectal Cancer	Drug combination validation
Yao et al.⁴⁸	LSN3074753	Oral gavage	RAF	Colorectal Cancer	Drug combination validation
Gymnopoulos et al.²⁸⁴	TR1801-ADC	Intravenous injection	CMet	Pan-cancer	Novel drug preclinical validation
Vaisitti et al.²⁸⁵	VLS-101	Intravenous injection	ROR1	Richter syndrome	Novel drug preclinical validation
Haikala et al.²³³	HER3-DXd	Intravenous injection	HER3	EGFR mutant non-small cell lung cancer	Novel drug preclinical validation

Back to article page

Table 4 PDX model in targeted therapy research

Search

Quick links